383 related articles for article (PubMed ID: 14695335)
1. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance.
Holzbeierlein J; Lal P; LaTulippe E; Smith A; Satagopan J; Zhang L; Ryan C; Smith S; Scher H; Scardino P; Reuter V; Gerald WL
Am J Pathol; 2004 Jan; 164(1):217-27. PubMed ID: 14695335
[TBL] [Abstract][Full Text] [Related]
2. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M; Latham DE; Delaney MA; Chakravarti A
Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
[TBL] [Abstract][Full Text] [Related]
4. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression.
Ryan CJ; Smith A; Lal P; Satagopan J; Reuter V; Scardino P; Gerald W; Scher HI
Urology; 2006 Oct; 68(4):834-9. PubMed ID: 17070363
[TBL] [Abstract][Full Text] [Related]
5. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence.
D'Antonio JM; Ma C; Monzon FA; Pflug BR
Prostate; 2008 May; 68(7):698-714. PubMed ID: 18302219
[TBL] [Abstract][Full Text] [Related]
7. Gene amplifications associated with the development of hormone-resistant prostate cancer.
Edwards J; Krishna NS; Witton CJ; Bartlett JM
Clin Cancer Res; 2003 Nov; 9(14):5271-81. PubMed ID: 14614009
[TBL] [Abstract][Full Text] [Related]
8. Molecular alterations in primary prostate cancer after androgen ablation therapy.
Best CJ; Gillespie JW; Yi Y; Chandramouli GV; Perlmutter MA; Gathright Y; Erickson HS; Georgevich L; Tangrea MA; Duray PH; González S; Velasco A; Linehan WM; Matusik RJ; Price DK; Figg WD; Emmert-Buck MR; Chuaqui RF
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6823-34. PubMed ID: 16203770
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.
Kawabata R; Oie S; Oka T; Takahashi M; Kanayama H; Itoh K
Int J Oncol; 2011 Mar; 38(3):665-76. PubMed ID: 21243325
[TBL] [Abstract][Full Text] [Related]
10. A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.
Cai Y; Lee YF; Li G; Liu S; Bao BY; Huang J; Hsu CL; Chang C
Int J Cancer; 2008 Jul; 123(1):195-201. PubMed ID: 18386814
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms leading to the development of hormone-resistant prostate cancer.
Kasper S; Cookson MS
Urol Clin North Am; 2006 May; 33(2):201-10, vii. PubMed ID: 16631458
[TBL] [Abstract][Full Text] [Related]
12. Chemical castration and anti-androgens induce differential gene expression in prostate cancer.
Lehmusvaara S; Erkkilä T; Urbanucci A; Waltering K; Seppälä J; Larjo A; Tuominen VJ; Isola J; Kujala P; Lähdesmäki H; Kaipia A; Tammela TLj; Visakorpi T
J Pathol; 2012 Jul; 227(3):336-45. PubMed ID: 22431170
[TBL] [Abstract][Full Text] [Related]
13. Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism.
Wang Y; Shao C; Shi CH; Zhang L; Yue HH; Wang PF; Yang B; Zhang YT; Liu F; Qin WJ; Wang H; Shao GX
Asian J Androl; 2005 Dec; 7(4):375-80. PubMed ID: 16281084
[TBL] [Abstract][Full Text] [Related]
14. Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
Takizawa I; Hara N; Nishiyama T; Isahaya E; Hoshii T; Takahashi K
J Urol; 2010 Nov; 184(5):1971-6. PubMed ID: 20884032
[TBL] [Abstract][Full Text] [Related]
15. A gene transcription signature associated with hormone independence in a subset of both breast and prostate cancers.
Creighton CJ
BMC Genomics; 2007 Jun; 8():199. PubMed ID: 17598908
[TBL] [Abstract][Full Text] [Related]
16. Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer.
Malinowska K; Cavarretta IT; Susani M; Wrulich OA; Uberall F; Kenner L; Culig Z
Prostate; 2009 Jul; 69(10):1109-18. PubMed ID: 19353593
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression.
Salah Z; Maoz M; Cohen I; Pizov G; Pode D; Runge MS; Bar-Shavit R
FASEB J; 2005 Jan; 19(1):62-72. PubMed ID: 15629896
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
19. Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak.
Castilla C; Congregado B; Chinchón D; Torrubia FJ; Japón MA; Sáez C
Endocrinology; 2006 Oct; 147(10):4960-7. PubMed ID: 16794010
[TBL] [Abstract][Full Text] [Related]
20. Differentially expressed genes in the prostate cancer cell line LNCaP after exposure to androgen and anti-androgen.
Coutinho-Camillo CM; Salaorni S; Sarkis AS; Nagai MA
Cancer Genet Cytogenet; 2006 Apr; 166(2):130-8. PubMed ID: 16631469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
